60 Degrees Pharma Declares IRB Approval of Clinical Study

60 Degrees Pharmaceuticals, Inc, a leading firm focused on growing new medicines for infectious ailments, reported morals endorsement of an open label, extended access study of the ARAKODA® routine of tafenoquine in blend with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis.

The study's objective is to confirm an earlier case series of tafenoquine conducted by the Yale School of Public Health (YSPH) in April 2024 and published in the journal Clinical Infectious Diseases that found a cure rate of 80% for babesiosis in humans in a similar population. Five immunosuppressed patients who received weekly tafenoquine following a loading dose in conjunction with standard of care medications demonstrated a cure rate of 80% (30-100%) in the YSPH case series with a 95% confidence interval.

“Tafenoquine is showing exciting promise in addressing babesiosis within various human patient populations,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow, PhD. “With babesiosis rates now rising in key regions of the United States and given the very serious nature of this tick-borne illness, especially in the elderly and immunocompromised people, we are moving quickly in an effort to confirm Yale’s observations while advancing the clinical program for hospitalized babesiosis patients which is now enrolling at Tufts Medical Center. Ultimately, we aim to re-purpose tafenoquine as a new babesiosis treatment.”